BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 19435898)

  • 1. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.
    Mukherjee B; McEllin B; Camacho CV; Tomimatsu N; Sirasanagandala S; Nannepaga S; Hatanpaa KJ; Mickey B; Madden C; Maher E; Boothman DA; Furnari F; Cavenee WK; Bachoo RM; Burma S
    Cancer Res; 2009 May; 69(10):4252-9. PubMed ID: 19435898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
    Gil del Alcazar CR; Hardebeck MC; Mukherjee B; Tomimatsu N; Gao X; Yan J; Xie XJ; Bachoo R; Li L; Habib AA; Burma S
    Clin Cancer Res; 2014 Mar; 20(5):1235-48. PubMed ID: 24366691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.
    Golding SE; Morgan RN; Adams BR; Hawkins AJ; Povirk LF; Valerie K
    Cancer Biol Ther; 2009 Apr; 8(8):730-8. PubMed ID: 19252415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA-PKcs deficiency inhibits glioblastoma cell-derived angiogenesis after ionizing radiation.
    Liu Y; Zhang L; Liu Y; Sun C; Zhang H; Miao G; Di CX; Zhou X; Zhou R; Wang Z
    J Cell Physiol; 2015 May; 230(5):1094-103. PubMed ID: 25294801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
    Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
    Struve N; Binder ZA; Stead LF; Brend T; Bagley SJ; Faulkner C; Ott L; Müller-Goebel J; Weik AS; Hoffer K; Krug L; Rieckmann T; Bußmann L; Henze M; Morrissette JJD; Kurian KM; Schüller U; Petersen C; Rothkamm K; O Rourke DM; Short SC; Kriegs M
    Oncogene; 2020 Apr; 39(15):3041-3055. PubMed ID: 32066879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
    McEllin B; Camacho CV; Mukherjee B; Hahm B; Tomimatsu N; Bachoo RM; Burma S
    Cancer Res; 2010 Jul; 70(13):5457-64. PubMed ID: 20530668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sp1 Upregulation Bolsters the Radioresistance of Glioblastoma Cells by Promoting Double Strand Breaks Repair.
    Liu X; Sun C; Wang Q; Li P; Zhao T; Li Q
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma.
    Reichert S; Rödel C; Mirsch J; Harter PN; Tomicic MT; Mittelbronn M; Kaina B; Rödel F
    Radiother Oncol; 2011 Oct; 101(1):51-8. PubMed ID: 21852011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
    Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
    Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
    Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear GSK3β induces DNA double-strand break repair by phosphorylating 53BP1 in glioblastoma.
    Yang Y; Lei T; Du S; Tong R; Wang H; Yang J; Huang J; Sun M; Wang Y; Dong Z
    Int J Oncol; 2018 Mar; 52(3):709-720. PubMed ID: 29328365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
    Sampson JH; Heimberger AB; Archer GE; Aldape KD; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling RJ; Shi W; Vredenburgh JJ; Bigner DD
    J Clin Oncol; 2010 Nov; 28(31):4722-9. PubMed ID: 20921459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
    Struve N; Riedel M; Schulte A; Rieckmann T; Grob TJ; Gal A; Rothkamm K; Lamszus K; Petersen C; Dikomey E; Kriegs M
    Oncotarget; 2015 Oct; 6(32):33867-77. PubMed ID: 26418954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
    Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
    BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin.
    Li B; Yuan M; Kim IA; Chang CM; Bernhard EJ; Shu HK
    Oncogene; 2004 Jun; 23(26):4594-602. PubMed ID: 15077177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.